Accelerate the Translation of Modulator & Treg Cell Therapies to Redefine Immune Tolerance for Autoimmune, Inflammatory, & Neurodegenerative Diseases

With Nobel Prize recognition, clinical advances by Nektar Therapeutics and ORCA-T’s potential as the first FDA-approved Treg cell therapy, Treg therapies are making waves.

At the 8th Treg-Directed Therapies Summit, Treg experts including Quell Therapeutics, Nektar Therapeutics, Sanofi, Yale and more, converge to overcome key challenges from cell targeting, Treg mechanisms of action and cytokine interactions, to indication selection, GMP and regulatory uncertainty, clinical trial design and established efficacy endpoints to push the boundaries of Treg application and clinical success. 

Over three action-packed days, enjoy industry-tailored, data-packed presentations and interactive sessions led by pioneering companies unveiling their path to success, to benchmark against the community. 

More info: Treg Directed Therapies